Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Michael R Migden"'
Publikováno v:
Oncotarget
Although basal cell carcinoma (BCC) is often managed successfully with surgery, patients with locally advanced BCC (laBCC) or metastatic BCC (mBCC) who are not candidates for surgery or radiotherapy have limited treatment options. Most BCCs result fr
Publikováno v:
Journal of Drugs in Dermatology. 20:156-165
Basal cell carcinoma (BCC) is the most common malignancy in fair-skinned populations. Most cases are successfully treated with surgery, but in advanced BCCmdash;including locally advanced BCC and metastatic BCCmdash;surgery is likely to result in sub
Autor:
Ruth Plummer, Ralf Gutzmer, Anne Lynn S. Chang, John T. Lear, Martin Kaatz, Uwe Trefzer, Alexandros Stratigos, Carmen Loquai, Luc Dirix, Patrick Combemale, Nicholas Squittieri, Karl D. Lewis, Reinhard Dummer, Michael R. Migden, A Guminksi, Ragini R. Kudchadkar, H.-J. Schulze
Publikováno v:
British Journal of Dermatology. 182:1369-1378
Background: Basal cell carcinomas (BCCs) exhibit aberrant activation of the hedgehog pathway. Sonidegib is a hedgehog pathway inhibitor approved for the treatment of locally advanced BCC (laBCC) and metastatic BCC (mBCC) based on primary results of t
Autor:
Reinhard Dummer, Michael R. Migden, Alexander Guminski, Nicholas Squittieri, John T. Lear, Liang Joo Leow
Publikováno v:
Journal of the American Academy of Dermatology. 84(4)
Autor:
Nicholas Squittieri, Alexander Guminski, Caroline Robert, Carmen Loquai, James M. Spencer, Felix Kiecker, Aaron S. Farberg, Kurt Gebauer, Reinhard Dummer, Michael R. Migden
Publikováno v:
Journal of the American Academy of Dermatology. 85:AB89
Autor:
Aleksandar Sekulic, Michael R. Migden, Nicole Basset-Seguin, Claus Garbe, Anja Gesierich, Christopher D. Lao, Chris Miller, Laurent Mortier, Dedee F. Murrell, Omid Hamid, Jorge F. Quevedo, Jeannie Hou, Edward McKenna, Natalie Dimier, Sarah Williams, Dirk Schadendorf, Axel Hauschild, for the ERIVANCE BCC Investigators
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-10 (2017)
BMC Cancer
BMC Cancer
In the primary analysis of the ERIVANCE BCC trial, vismodegib, the first US Food and Drug Administration–approved Hedgehog pathway inhibitor, showed objective response rates (ORRs) by independent review facility (IRF) of 30% and 43% in metastatic b
Publikováno v:
OncoTargets and therapy
Basal cell carcinoma (BCC) is the most common nonmelanoma skin cancer. If left untreated, BCCs can become locally aggressive or even metastasize. Currently available treatments include local destruction, surgery, and radiation. Systemic options for a
Publikováno v:
Future Oncology. 12:2095-2105
The Hedgehog inhibitors are promising alternative for patients with advanced basal cell carcinoma that are not amenable to radiotherapy or surgery. Sonidegib, also known as LDE225, is an orally available SMO antagonist that was recently approved by t
Autor:
Reinhard Dummer, Li Liu, John T. Lear, Michael R. Migden, Alexander Guminski, Nicholas Squittieri
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 4:s68
not available.
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 8 (2016)
Treatment of locally advanced basal cell carcinomas (laBCCs) with large, aggressive, destructive, and disfiguring tumors, or metastatic disease is challenging. Dysregulation of the Hedgehog (Hh) signaling pathway has been identified in the vast major